Marco Colombi
Impact in
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer
- Metabolism, Diabetes, and Cancer
- RNA modifications and cancer
Papers in
-
- Metabolism, Diabetes, and Cancer 4
- PI3K/AKT/mTOR signaling in cancer 3
- Oncology 6
- Cancer-related Molecular Pathways 3
- Co-authors
- Michael N. Hall (15 shared papers)Christoph Moroni (6 shared papers)Don Benjamin (4 shared papers)Suzette Moes (6 shared papers)Sravanth K. Hindupur (5 shared papers)Markus H. Heim (6 shared papers)Eva Dazert (6 shared papers)Paul Jenoe (3 shared papers)
- Journals
- Histochemistry and Cell Biology (4 papers)Oncogene (2 papers)Nature Communications (1 paper)Cell Reports (1 paper)Nature Reviews Drug Discovery (1 paper)
- Partner nations
- SwitzerlandSpainUnited States
In The Last Decade
Marco Colombi
23 papers receiving 2.5k citations
Marco Colombi's Hit Papers
Peers
Comparison fields: 5 of 108
- Cancer Research 613
- Molecular Biology 1.5k
- Biochemistry 124
- Physiology 371
- Aging 24
Countries citing papers authored by Marco Colombi
This map shows the geographic impact of Marco Colombi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Colombi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Colombi more than expected).
Fields of papers citing papers by Marco Colombi
This network shows the impact of papers produced by Marco Colombi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Colombi. The network helps show where Marco Colombi may publish in the future.
Co-authors
The 25 scholars most cited alongside Marco Colombi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Rapamycin passes the torch: a new generation of mTOR inhibitors Hit paper breakdown → | 2011 | 782 |
| 2 | Insulin resistance causes inflammation in adipose tissue Hit paper breakdown → | 2018 | 348 |
| 3 | 2017 | 303 | |
| 4 | 2018 | 281 | |
| 5 | 2018 | 169 | |
| 6 | Arginine reprograms metabolism in liver cancer via RBM39 Hit paper breakdown → | 2023 | 145 |
| 7 | 2016 | 112 | |
| 8 | 2022 | 88 | |
| 9 | 2016 | 62 | |
| 10 | 2016 | 54 | |
| 11 | 2010 | 37 | |
| 12 | 2019 | 19 | |
| 13 | 2022 | 18 | |
| 14 | 1990 | 12 | |
| 15 | 2022 | 12 | |
| 16 | 1990 | 11 | |
| 17 | 2021 | 10 | |
| 18 | 1999 | 10 | |
| 19 | 1997 | 6 | |
| 20 | 1990 | 3 |
About Marco Colombi
Marco Colombi is a scholar working on Molecular Biology, Oncology, Cancer Research, Surgery and Physiology, having authored 23 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (5 papers), Metabolism, Diabetes, and Cancer (4 papers), Adipose Tissue and Metabolism (4 papers), Pancreatic function and diabetes (3 papers), Cancer, Lipids, and Metabolism (3 papers), Cancer-related Molecular Pathways (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Metabolism and Genetic Disorders (2 papers). The work is most often cited by research in Cancer Research (613 citations), Molecular Biology (1.5k citations), Biochemistry (124 citations), Physiology (371 citations) and Aging (24 citations). Marco Colombi has collaborated with scholars based in Switzerland, Spain and United States. Frequent co-authors include Michael N. Hall, Christoph Moroni, Don Benjamin, Suzette Moes, Sravanth K. Hindupur, Markus H. Heim, Eva Dazert, Paul Jenoe, Mitsugu Shimobayashi and Yakir Guri. Their work appears in journals such as Histochemistry and Cell Biology, Oncogene, Nature Communications, Cell Reports and Nature Reviews Drug Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.